A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97

doi:10.1186/s13148-018-0475-2

Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/57931

Registo completo

Campo DC	Valor	Idioma
dc.contributor.author	Ramalho-Carvalho, João	por
dc.contributor.author	Gonçalves, Celine Saraiva	por
dc.contributor.author	Graça, Inês	por
dc.contributor.author	Bidarra, David	por
dc.contributor.author	Pereira-Silva, Eva	por
dc.contributor.author	Salta, Sofia	por
dc.contributor.author	Godinho, Maria Inês	por
dc.contributor.author	Gomez, Antonio	por
dc.contributor.author	Esteller, Manel	por
dc.contributor.author	Costa, Bruno Marques	por
dc.contributor.author	Henrique, Rui	por
dc.contributor.author	Jerónimo, Carmen	por
dc.date.accessioned	2019-01-08T15:57:01Z	-
dc.date.available	2019-01-08T15:57:01Z	-
dc.date.issued	2018	-
dc.identifier.citation	Ramalho-Carvalho, J., Gonçalves, C. S., Graça, I., Bidarra, D., Pereira-Silva, E., Salta, S., ... & Henrique, R. (2018). A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97. Clinical epigenetics, 10(1), 40	por
dc.identifier.issn	1868-7075	-
dc.identifier.uri	https://hdl.handle.net/1822/57931	-
dc.description.abstract	Prostate cancer (PCa) is a major cause of morbidity and mortality in men worldwide. MicroRNAs are globally downregulated in PCa, especially in poorly differentiated tumors. Nonetheless, the underlying mechanisms are still elusive. Herein, using combined analysis of microRNAs expression and genomewide DNA methylation, we aimed to identify epigenetically downregulated microRNAs in PCa.	por
dc.description.sponsorship	Research Center of Portuguese Oncology Institute of Porto (FB-GEBC-27 and 19-CI-IPOP-2016). JR-C and CSG are supported by FCT- Fundação para a Ciência e Tecnologia PhD fellowships (SFRH/BD/71293/2010 and SFRH/BD/92786/2013), SS is supported by a PhD fellowship IPO/ESTIMA-1 NORTE-01-0145-FEDER-000027, and IG is a research fellow from the strategic funding of FCT (PCT: PEst- UID/DTP/00776/2013 and COMPETE: POCI-01-0145-FEDER-006868). BMC is funded by FCT-Fundação para a Ciência e a Tecnologia (IF/00601/2012)	por
dc.language.iso	eng	por
dc.publisher	Springer Nature	por
dc.rights	openAccess	por
dc.subject	miR-152-3p	por
dc.subject	Prostate cancer	por
dc.subject	Cell cycle	por
dc.subject	DNA methylation	por
dc.subject	CRISPR	por
dc.subject	TMEM97	por
dc.title	A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97	por
dc.type	article	por
dc.peerreviewed	yes	por
dc.relation.publisherversion	https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-018-0475-2	por
oaire.citationStartPage	40	por
oaire.citationIssue	1	por
oaire.citationVolume	10	por
dc.identifier.eissn	1868-7083	-
dc.identifier.doi	10.1186/s13148-018-0475-2	por
dc.identifier.pmid	29599847	por
dc.subject.fos	Ciências Médicas::Medicina Básica	por
dc.description.publicationversion	info:eu-repo/semantics/publishedVersion	por
dc.subject.wos	Science & Technology	por
sdum.journal	Clinical Epigenetics	por
Aparece nas coleções:	ICVS - Artigos em revistas internacionais / Papers in international journals

Ficheiros deste registo:

Ficheiro	Descrição	Tamanho	Formato
RAMALH~1.PDF		2,65 MB	Adobe PDF	Ver/Abrir

Ver registo simples Sugerir correção Estatísticas

Citations

Altmetrics